A Phase 1 interventional study of Azirkitug and Budigalimab in Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Micro Satellite Stable Colorectal Cancer, sponsored by AbbVie. Recruiting at 48 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by AbbVie · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Carcinoma, Non-Small-Cell Lung by AbbVie — 8 open to participants now, 14 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · AbbVie.
Among the 48 studies in Carcinoma, Non-Small-Cell Lung by AbbVie, this one is the 4th largest by planned enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2021, is one of 21 in phase 1, reaches primary completion later than 4 of the 13 other live ones, and was the 36th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →8 of the 48 studies in Carcinoma, Non-Small-Cell Lung by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Puerto Rico
Ages 18+
AbbVie · Sites in United States
Ages 18+
AbbVie · Sites in United States, Australia, Austria and 17 more countries
Ages 18+
AbbVie · Sites in United States, Argentina, Australia and 14 more countries
Ages 18+
AbbVie · Sites in United States, Brazil, China and 4 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 18 · Phase 3 9
First in 2004; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 694 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 135 across the 46 interventional studies, 579 across the 1 observational. Of the 32 that completed or were terminated, 5 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
4 of the studies in Carcinoma, Non-Small-Cell Lung by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03893955AbbVieA Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | 2027-03 |
| NCT05005403AbbVieStudy to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan | 2027-07 |
| NCT06772623AbbVieStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | 2027-11 |
| NCT05029882AbbVieStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 48 studies in Carcinoma, Non-Small-Cell Lung by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which cancer cells form in the tissues of the head and neck. The purpose of this study is to assess adverse events and pharmacokinetics of azirkitug as a monotherapy and in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan.
Bevacizumab is an approved product, while budigalimab, azirkitug, and telisotuzumab adizutecan are investigational drugs being developed for the treatment of NSCLC, HNSCC, and other solid tumors. Study doctors put the participants in groups called treatment arms. The maximum-tolerated dose (MTD)/maximum administered dose (MAD) of azirkitug will be explored. Each treatment arm receives a different dose of azirkitug in monotherapy and in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan. Approximately 694 adult participants will be enrolled in the study across approximately 80 sites worldwide.
Participants will receive azirkitug as a monotherapy or in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan as an Intravenous (IV) Infusion for an estimated treatment period of up to 2 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Azirkitug.
Drug: Azirkitug
Participants will receive Azirkitug in combination with budigalimab.
Drug: Azirkitug · Drug: Budigalimab
Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion.
Drug: Azirkitug
Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion in combination with budigalimab.
Drug: Azirkitug · Drug: Budigalimab
Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion in combination with budigalimab.
Drug: Azirkitug · Drug: Budigalimab
Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion.
Drug: Azirkitug
Participants will receive Azirkitug in combination with budigalimab.
Drug: Azirkitug · Drug: Budigalimab
Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion.
Drug: Azirkitug
Participants will receive Azirkitug in combination with budigalimab.
Drug: Azirkitug · Drug: Budigalimab
Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion in combination with budigalimab.
Drug: Azirkitug · Drug: Budigalimab
Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion in combination with budigalimab.
Drug: Azirkitug · Drug: Budigalimab
Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion in combination with budigalimab.
Drug: Azirkitug · Drug: Budigalimab
Participants will receive Azirkitug in combination with bevacizumab.
Drug: Azirkitug · Drug: Bevacizumab
Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion in combination with bevacizumab.
Drug: Azirkitug · Drug: Bevacizumab
Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion in combination with budigalimab.
Drug: Azirkitug · Drug: Budigalimab
Participants will receive Azirkitug in combination with telisotuzumab adizutecan.
Drug: Azirkitug · Drug: Telisotuzumab Adizutecan
Participants will receive Azirkitug at recommended dose determined in the safety lead in portion in combination with telisotuzumab adizutecan.
Drug: Azirkitug · Drug: Telisotuzumab Adizutecan
Intravenous (IV) Infusion
Intravenous (IV) Infusion
Intravenous (IV) Infusion
Intravenous (IV) Infusion
Number of Participants with Adverse Events (AE)
An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Time frame: Up to 2 Years
Maximum Observed Serum Concentration (Cmax) of Azirkitug
Maximum Observed Serum Concentration (Cmax) of azirkitug.
Time frame: Up to 2 Years
Time to Maximum Observed Serum Concentration (Tmax) of Azirkitug
Time to maximum Observed Serum Concentration (Tmax) of azirkitug.
Time frame: Up to 2 Years
Terminal Elimination Half-Life (t1/2) of Azirkitug
Terminal elimination half-life (t1/2) of azirkitug.
Time frame: Up to 2 Years
Area Under the Serum Concentration Versus Time Curve (AUC) of Azirkitug
Area under the serum concentration versus time curve (AUC) of azirkitug.
Time frame: Up to 2 Years
Azirkitug Antidrug Antibody (ADA)
Incidence and concentration of azirkitug anti-drug antibodies.
Time frame: Up to 2 Years
Azirkitug Neutralizing Antidrug Antibody (nADA)
Incidence and concentration of azirkitug neutralizing anti-drug antibodies.
Time frame: Up to 2 Years
Cmax of Budigalimab
Cmax of budigalimab.
Time frame: Up to 2 Years
Tmax of Budigalimab
Tmax of budigalimab.
Time frame: Up to 2 Years
t1/2 of Budigalimab
t1/2 of budigalimab.
Time frame: Up to 2 Years
AUC of Budigalimab
AUC of budigalimab.
Time frame: Up to 2 Years
Budigalimab ADA
Incidence and concentration of budigalimab ADA.
Time frame: Up to 2 Years
Budigalimab nADA
Incidence and concentration of budigalimab nADA.
Time frame: Up to 2 Years
Cmax of Telisotuzumab Adizutecan
Cmax of telisotuzumab adizutecan.
Time frame: Up to 2 Years
Tmax of Telisotuzumab Adizutecan
Tmax of telisotuzumab adizutecan.
Time frame: Up to 2 Years
t1/2 of Telisotuzumab Adizutecan
t1/2 of telisotuzumab adizutecan.
Time frame: Up to 2 Years
AUC of Telisotuzumab Adizutecan
AUC of telisotuzumab adizutecan.
Time frame: Up to 2 Years
Telisotuzumab Adizutecan ADA
Incidence and concentration of telisotuzumab adizutecan ADA.
Time frame: Up to 2 Years
Telisotuzumab Adizutecan nADA
Incidence and concentration of telisotuzumab adizutecan nADA.
Time frame: Up to 2 Years
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2021 (actual). Primary completion is estimated for Jul 2027, 68 months after the start.
Of 473 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 68 months is above that.
Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →